ZA991393B - Method of treating impotence due to spinal cord injury. - Google Patents

Method of treating impotence due to spinal cord injury.

Info

Publication number
ZA991393B
ZA991393B ZA9901393A ZA991393A ZA991393B ZA 991393 B ZA991393 B ZA 991393B ZA 9901393 A ZA9901393 A ZA 9901393A ZA 991393 A ZA991393 A ZA 991393A ZA 991393 B ZA991393 B ZA 991393B
Authority
ZA
South Africa
Prior art keywords
spinal cord
cord injury
impotence due
treating impotence
male
Prior art date
Application number
ZA9901393A
Inventor
Murray Craig Mayton
Ian Howard Osterloh
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of ZA991393B publication Critical patent/ZA991393B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrotherapy Devices (AREA)

Abstract

A class of cGMP PDE inhibitors, including sidenafil and pharmaceutically acceptable salts thereof, which can be used to treat sexual dysfunction in male and female animals, especially humans, with a spinal cord injury. The invention can be used to treat sexual dysfunction in male animals that exhibit essentially no residual penile function.
ZA9901393A 1998-02-23 1999-02-22 Method of treating impotence due to spinal cord injury. ZA991393B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7558098P 1998-02-23 1998-02-23

Publications (1)

Publication Number Publication Date
ZA991393B true ZA991393B (en) 2000-08-22

Family

ID=22126701

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901393A ZA991393B (en) 1998-02-23 1999-02-22 Method of treating impotence due to spinal cord injury.

Country Status (17)

Country Link
US (1) US20060040935A1 (en)
EP (1) EP0951908B1 (en)
JP (1) JPH11315025A (en)
KR (1) KR19990072798A (en)
AT (1) ATE279194T1 (en)
AU (1) AU755402B2 (en)
CA (1) CA2262268C (en)
DE (1) DE69921008T2 (en)
DK (1) DK0951908T3 (en)
ES (1) ES2226281T3 (en)
HU (1) HUP9900438A3 (en)
IL (1) IL128532A0 (en)
MY (1) MY133446A (en)
NZ (1) NZ334333A (en)
PT (1) PT951908E (en)
TW (1) TW542719B (en)
ZA (1) ZA991393B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
GT199900061A (en) * 1998-05-15 2000-10-14 Pfizer PHARMACEUTICAL FORMULATIONS.
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (en) * 1998-07-31 2000-02-03 Hexal Ag Transmucosal therapeutic system for the use of sildenafil
DE19834507A1 (en) * 1998-07-31 2000-02-03 Hexal Ag Pharmaceutical, water-soluble tablet formulation for the use of sildenafil
AU4663100A (en) 1999-04-30 2000-11-17 Lilly Icos Llc Treatment of female arousal disorder
KR20020062770A (en) 1999-12-24 2002-07-29 바이엘 악티엔게젤샤프트 Imidazo 1,3,5 triazinones and the Use Thereof
KR20010016165A (en) * 2000-11-16 2001-03-05 정순학 The topical therapeutic preparations for sexual dysfunctions of men and women
KR100393160B1 (en) * 2001-06-14 2003-07-31 한국과학기술연구원 Novel Pyrazolopyrimidinethione Derivatives, Preparation Methods Thereof and Their Use as Therapeutics for Erectile Dysfunction
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
JP2007537247A (en) 2004-05-11 2007-12-20 エモーショナル ブレイン ビー．ブイ． Pharmaceutical formulations and methods of use thereof in the treatment of female sexual dysfunction
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008142396A1 (en) * 2007-05-18 2008-11-27 Anthony Denis Maher Methods of assessing male fertility using a uridine marker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
CA2262268A1 (en) 1999-08-23
AU755402B2 (en) 2002-12-12
MY133446A (en) 2007-11-30
DE69921008T2 (en) 2006-02-02
ATE279194T1 (en) 2004-10-15
HUP9900438A2 (en) 2000-03-28
EP0951908B1 (en) 2004-10-13
PT951908E (en) 2005-01-31
IL128532A0 (en) 2000-01-31
DE69921008D1 (en) 2004-11-18
NZ334333A (en) 2000-11-24
AU1839099A (en) 1999-09-09
ES2226281T3 (en) 2005-03-16
HU9900438D0 (en) 1999-04-28
KR19990072798A (en) 1999-09-27
TW542719B (en) 2003-07-21
CA2262268C (en) 2003-07-29
US20060040935A1 (en) 2006-02-23
DK0951908T3 (en) 2004-12-27
HUP9900438A3 (en) 2002-01-28
EP0951908A3 (en) 2000-08-16
JPH11315025A (en) 1999-11-16
EP0951908A2 (en) 1999-10-27

Similar Documents

Publication Publication Date Title
IL128532A0 (en) Method of treating impotence due to spinal cord injury
MY117967A (en) Intranasal formulations for treating sexual disorders
MX9703868A (en) cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION.
ZA200206612B (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
EP1005336A4 (en) Improved methods and compositions for treating male erectile dysfunction
IL153492A0 (en) Treatment of male sexual dysfunction
WO1994004120A3 (en) Methods of treating sexual dysfunction in animals with and h agonist
NZ270871A (en) Method for treating erectile dysfunction
ZA914135B (en) Method of treating impotence
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
ID24184A (en) MEDICINE FOR TREATMENT OF EFFECTIVE DISFUNCTIONS
EP1150698A4 (en) Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
MD1979F1 (en) Method of secondary cataract treatment
WO2005051368A3 (en) Phosphodiesterase v inhibitor formulations
WO1996036339A3 (en) Use of dihydrotestosterone compounds for treating male sexual dysfunction
AU2001281396A1 (en) Novel compositions and methods for treatment of male erectile dysfunction
GB9928178D0 (en) Agent for the treatment of male and female sexual dysfunction
CA2203379A1 (en) Cgmp-pde inhibitors for the treatment of erectile dysfunction
ZA923961B (en) Use of atipamezole
GB0030647D0 (en) Treatment of male sexual dysfunction
SI1505997T1 (en) Formulations useful in the treatment of male and female impotence
ECSP993027A (en) INTRANASAL FORMULATIONS FOR SEXUAL DISORDERS